What list inclusion would not permit Even a final listing would not turn BPC-157 into an over-the-counter supplement, authorize unrestricted bulk manufacturing, or validate every advertised claim
Safety, tolerability, PK, and PD in people with overweight/obesity
The range of potential symptoms coming from the over-accumulation of mercury is quite large, so the following is not an exhaustive list (3): Tremors Emotional changes (such as mood swings, irritability, nervousness, excessive shyness) Insomnia Neuromuscular changes (such as weakness, muscle atrophy, twitching) Headaches Disturbances in sensations Changes in nerve responses and/or Poor performance on tests of mental function Loss of peripheral vision Pins and needles feelings, usually in the hands, feet, and around the mouth Lack of coordination of movements Impairment of speech, hearing, walking, and/or Muscle weakness It is also noted that Higher exposures may also cause kidney effects, respiratory failure and death (3)
We assume that Novo Nordisk is capable of growing GLP-1 sales across indications from roughly $24 billion in 2023 to nearly $75 billion by 2031, prior to the patent expiration for semaglutide, the molecule in Ozempic and Wegovy
Alternative Medicine Review, 10 (3),193-203
M.WalbotV
